Aβ Peptide Aggregation Inhibition Assay
The formation of amyloid β (Aβ) aggregates is one of the major hallmarks of Alzheimer's disease (AD), which is associated with the progressive cognitive decline in AD patients. To inhibit or interfere Aβ aggregation are thought to be potential effective managing the progression of AD. Therefore, compounds that are developed to disrupt Aβ aggregation should be in high demand.
Figure 1 Schematic of amyloid formation from monomer, heterogeneous oligomers / protofbrils, to mature fbrils.
Creative Bioarray offers customized in vitro models for Aβ peptide aggregation inhibition assay, including primary neuronal cultures, cell lines, iPS cells with genetic modifications, which are phenotypically closer to those observed in the aged neuronal network and mimic the development of AD. Using these in vitro models, the direct effects of reducing Aβ aggregate formation by compounds will be carefully evaluated.
We provide this powerful and versatile tool for developing potential AD therapy directly as well as basic research to help our customers who wish to understand more about the underlying mechanisms of AD from which they could facilitate the process of drug development.
Study Examples
Figure 2 Transthyretin (TTRs) inhibit Aβ oligomer and fibril formation.
Quotation and ordering
Contact us if you have any questions. Our customer service representatives are available 24hr a day.
References
- Bi TM.; et al. The role of alpha-sheet in amyloid oligomer aggregation and toxicity. Yale J Biol Med. 2018, 91(3): 247-255.
- Li X.; et al. Mechanisms of transthyretin inhibition of β -amyloid aggregation in vitro. J Neurosci. 2013, 33(50): 19423-1933.
